14 Indole based prostate cancer agents
-
Sunil Kumar
Abstract
Cancer weakens the immune system which fails to fight against the rapidly growing cells. Among the various types of cancers, prostate cancer (PCa) is causing greater number of deaths in men after lung cancer, demanding advancement to prevent, detect and treat PCa. Several small molecule heterocycles and few peptides are being used as oncological drugs targeting PCa. Heterocycles are playing crucial role in the development of novel cancer chemotherapeutics as well as immunotherapeutics. Indole skeleton, being a privileged structure has been extensively used for the discovery of novel anticancer agents and the application of indole derivatives against breast cancer is well documented. The present article highlights the usefulness of indole linked heterocyclic compounds as well as the fused indole derivatives against prostate cancer.
Abstract
Cancer weakens the immune system which fails to fight against the rapidly growing cells. Among the various types of cancers, prostate cancer (PCa) is causing greater number of deaths in men after lung cancer, demanding advancement to prevent, detect and treat PCa. Several small molecule heterocycles and few peptides are being used as oncological drugs targeting PCa. Heterocycles are playing crucial role in the development of novel cancer chemotherapeutics as well as immunotherapeutics. Indole skeleton, being a privileged structure has been extensively used for the discovery of novel anticancer agents and the application of indole derivatives against breast cancer is well documented. The present article highlights the usefulness of indole linked heterocyclic compounds as well as the fused indole derivatives against prostate cancer.
Chapters in this book
- Frontmatter I
- Preface VII
- Contents IX
- List of contributing authors XVII
- 1 Naturally occurring, natural product inspired and synthetic heterocyclic anti-cancer drugs 1
- 2 Naturally occurring heterocyclic anticancer compounds 55
- 3 Lawsone (2-hydroxy-1,4-naphthaquinone) derived anticancer agents 83
- 4 Advances in heterocycles as DNA intercalating cancer drugs 111
- 5 Recent advances of heterocycle based anticancer hybrids 161
- 6 Fused pyrrolo-pyridines and pyrrolo-(iso) quinoline as anticancer agents 185
- 7 Updates on the versatile quinoline heterocycles as anticancer agents 249
- 8 Recent development of imidazole derivatives as potential anticancer agents 267
- 9 Recent developments in the synthesis and anti-cancer activity of acridine and xanthine-based molecules 307
- 10 Synthesis of new horizons in benzothiazole scaffold and used in anticancer drug development 343
- 11 Triazine based chemical entities for anticancer activity 387
- 12 Anticancer properties of arylchromenes and arylchromans: an overview 419
- 13 Anticancer potential of indole derivatives: an update 453
- 14 Indole based prostate cancer agents 479
- Index 503
Chapters in this book
- Frontmatter I
- Preface VII
- Contents IX
- List of contributing authors XVII
- 1 Naturally occurring, natural product inspired and synthetic heterocyclic anti-cancer drugs 1
- 2 Naturally occurring heterocyclic anticancer compounds 55
- 3 Lawsone (2-hydroxy-1,4-naphthaquinone) derived anticancer agents 83
- 4 Advances in heterocycles as DNA intercalating cancer drugs 111
- 5 Recent advances of heterocycle based anticancer hybrids 161
- 6 Fused pyrrolo-pyridines and pyrrolo-(iso) quinoline as anticancer agents 185
- 7 Updates on the versatile quinoline heterocycles as anticancer agents 249
- 8 Recent development of imidazole derivatives as potential anticancer agents 267
- 9 Recent developments in the synthesis and anti-cancer activity of acridine and xanthine-based molecules 307
- 10 Synthesis of new horizons in benzothiazole scaffold and used in anticancer drug development 343
- 11 Triazine based chemical entities for anticancer activity 387
- 12 Anticancer properties of arylchromenes and arylchromans: an overview 419
- 13 Anticancer potential of indole derivatives: an update 453
- 14 Indole based prostate cancer agents 479
- Index 503
